HONG KONG – Hangzhou-based Chinese oncology drugmaker Betta Pharmaceuticals Co. Ltd. said Chinese regulators have given a green light for the company to conduct clinical trials for its novel compound, BPI-17509. Developed in-house, the oral small molecule is designed to selectively target fibroblast growth factor receptor (FGFR) 1, 2 and 3 to treat intrahepatic cholangiocarcinoma, bladder cancer and lung squamous cell carcinoma, among other FGFR-relevant solid tumors.